CMPS CMPS
Company Profile ↓Company Overview
CMPS (CMPS) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +195.22% |
| 6 Months: | +106.07% |
| 3 Months: | +45.71% |
| 1 Month: | +4.54% |
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)61.58 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -13.60M | -19.53M | -21.77M | -25.42M | -27.26M | -25.54M | -31.79M | -32.66M | -34.06M | -38.57M | -43.32M | -47.90M | -49.62M | -42.93M | -40.54M | -42.90M |
| Net Income | -17.53M | -15.85M | -12.71M | -17.53M | -15.85M | -21.17M | -21.04M | -18.37M | -24.21M | -28.34M | -33.39M | -35.19M | -38.10M | -38.50M | -17.86M | -38.40M | -137.72M | 91.20M |
| Diluted EPS | -0.44 | -0.38 | -0.35 | -0.44 | -0.38 | -0.50 | -0.50 | -0.43 | -0.57 | -620.00 | -0.67 | -0.55 | -0.56 | -0.56 | -0.24 | -0.41 | -1.44 | -0.30 |
| R&D Expense | - | - | 6.88M | 11.35M | 12.20M | 15.36M | 15.92M | 13.98M | 19.04M | 19.82M | 21.53M | 24.90M | 29.07M | 32.93M | 30.88M | 30.32M | 27.32M | 26.48M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Income | -21.18M | -51.39M | -83.22M | -110.40M | -136.92M | -178.21M | -179.04M |
| Net Income | -19.61M | -60.33M | -71.74M | -91.50M | -118.46M | -155.12M | -287.86M |
| Diluted EPS | -2.62 | -3.55 | -1.79 | -2.16 | -2.32 | -2.30 | -3.08 |
| R&D Expense | 12.56M | 23.37M | 44.03M | 65.05M | 87.52M | 119.04M | 118.44M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 203.46M | 300.90M | 197.29M | 275.99M | 213.67M | 210.35M |
| Total Equity | -14.37M | -30.39M | 196.56M | 284.41M | 181.28M | 225.74M | 154.69M | -52.85M |
| Cash & Equivalents | - | 24.97M | 190.33M | 273.24M | 143.21M | 220.20M | 165.08M | 149.61M |
| Long Term Debt | - | - | - | - | 0 | 28.76M | 24.65M | 14.11M |
| Total Liabilities | - | - | 6.89M | 16.49M | 16.01M | 50.24M | 58.97M | 263.20M |
| Current Liabilities | - | - | 6.89M | 15.11M | 15.60M | 19.60M | 34.02M | 247.79M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -17.81M | -41.38M | -67.75M | -105.45M | -97.38M | -119.19M | -157.24M |
| Investing Cash Flow | -165.00K | -628.00K | -334.00K | -596.00K | -64.00K | 0 | - |
| Financing Cash Flow | 18.38M | 194.16M | 156.65M | 1.04M | 173.83M | 63.82M | 140.71M |
| Capital Expenditure | -165.00K | -131.00K | -334.00K | -596.00K | -66.00K | -0 | - |
| Free Cash Flow | -17.98M | -41.51M | -68.08M | -106.05M | -97.44M | -119.19M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 64.5% | -30.7% | -25.2% | -50.5% | -52.5% | -100.3% | 544.7% |
| ROCE % | - | -26.1% | -29.1% | -60.8% | -53.4% | -99.2% | 478.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CMPS
CMPS Stock Climbs Toward 2-Year Highs – What’s Driving This Rally? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPM3ZyTGNNaGl5U1BJY295aUp6SjM4eUJPd3VxQWRIX0h3aWRocTJoem1OUlBFU0x0YlBzcG50SmZDcUdCNFdaYWRndlZscFBxX0dCcnp6NVNtLXdJR056RHc4a3hTY3NFUHAtSUxpUHZvUHZrVEJnZENEQ190RXVheDloaEtUUVFBNHkwcn…
COMPASS PATHWAYS ($CMPS) Releases Q2 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQbkJyM3h1cE9ZYUFLVnlaeks5M3lQdDgxTEp5eGFiWF95ZW9NWkhFWWFUNlNJTlJCU1d4c3JyOUJsNVJ6TU91SDZoWUhXOU5MWTFoakw2VDA1SVZqQ21EMFozMjJhdWFVTlBUMGlXd3JmS01CaF9Nb2JfVnk4UEdfR0RGdGhROVNqYmhfdU…
COMPASS Pathways (CMPS) Is Up 8.8% After Q2 Net Loss Surges To US$254 Million – Has The Bull Case Changed? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxOdG1KZVQyMG9JNVRGZnpLbkduVm9vWjRiZ0FUX3hWN1haOHM0QTZOZEVzUUJBZnZjRnhVN3g4RzlJWkhIdU1kQTVDblZoUUZ0dTBLNFBzaUlWTmRJQ0NZUWdiTjhMNG9oZjFRX2VZRHJPMWNzZkxNRmFZWE1sdk94MkN2UU1ncWdhYmpiV3…
Oppenheimer reiterates Compass Pathways stock rating on FDA progress - Investing.com
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxPZnd2WEhFRGxLc2lRMExxODhsSVVNWGc1TU1aSTN2TkVmNVhUeFowajEyd2pKd1ptdjN4R1NFcWQ5VkJkSndIVWVKLTFGX3oyYzFxa18yQkRLbW1jQ2wxdVF3eG4yQ0NBbVhtVkl3bjluamxoWTBYZ1JUNHVtbEZ6bEpMVzZkelRIcFFTeF…
CMPS Stock Clocks Muted Gains But Analysts Back Psychedelic Drug’s Durability Ahead Of FDA Filing - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxNMjFhaEsxVWwtTjBVbGVhN3pQdjFoUjNzbEVmcVRraWUxb096N0R5YkpnSnlLcVFqMVRoaXQ1UWkxRHoyemd5RHgxS0RWQlN3MUduR25LSml3Ym4wamVRSkcxRnVxWlNOeGVDWHRrOG8tX2FrRldPckNNazR3MUhlc2NYbHhqdTA4dEdJUE…
Is COMPASS Pathways plc (CMPS) A Good Stock To Buy Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxON3BoZXYtVloyYXVJMHA0amx2TFNJT2JXVU9FS1pIQThER0lqZXFIS0htMTFGUFp5eHc1alc4ZVowOXZLU09hMVNfOUJkajRzWlhud1hZX2dveHJWaEJQSVluXzZBYzhTbXo0SUpTdlZadUdieHdxdTY0TlR4NEhab2NIVVI0cFRlS1ZfLV…
CMPS — Frequently Asked Questions
What is the current share price of CMPS?
As of 2026-08-05 17:25 PDT, CMPS trades at $13.58 on NASDAQ/NYSE. Its 52-week range is $4.08 to $15.07.
What is the P/E ratio of CMPS?
CMPS trades at a trailing price-to-earnings (P/E) ratio of -4.41.
Is CMPS a good stock to buy?
This page provides a data-driven analysis of CMPS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.